Real-world trends in biologic, oral systemic, and phototherapy in US patients with psoriasis or psoriatic arthritis

Singh, Partik; Silverberg, Jonathan I.

doi:10.1016/j.jaad.2020.01.045

Cited by 11 publications

(10 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result was in line with a previous retrospective database study carried out on PsA patients among the German population, showing that almost 19% of PsA patients were treated with bDMARDs between 2014 and 2017 [ 24 ]. In addition, a real-world trend in biologic therapy was described for US patients; systemic therapy was used in 20.9% (18.1–24.0%) of patients, most commonly with biologics [8.0% (6.2–10.3%)] [ 25 ]. However, a higher frequency of biological use among PsA patients (32.0%) was found in a real-world study in southern Italy [ 17 ], and the MAPP survey among the North American and European populations reported an approximately 31% biological use [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population

Perrone¹,

Losi

Filippi

et al. 2022

Rheumatol Ther

View full text Add to dashboard Cite

Introduction Real-world pharmacoutilization analysis of biological drugs in psoriatic arthritis (PsA) patients with the aim to evaluate biologic treatment patterns and pharmacoutilization among patients with PsA in Italy. Methods A retrospective study was conducted using administrative databases of Italian Entities. PsA patients were included and diagnosed by hospitalization and/or an active exemption code. Two analyses were performed: a cross-sectional for treatment patterns in patients enrolled among 2017–2020, and a longitudinal study during 2015 to investigate the pharmacoutilization, in terms of persistence and monthly maintenance dosage of biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). Patients with or without b/tsDMARDs prescriptions before inclusion were defined as bioexperienced or naïve, respectively. An analysis on ixekizumab-treated patients (IXE patients) from the 2017-to study ending was performed. Results PsA was diagnosed in 24,786 (2017), 27,221 (2018), 28,889 (2019), and 29,292 (2020) patients. Across 2017–2020, 31.1–40.5% of PsA patients were untreated with systemic medications, and 16.4–18.8% were under biological therapies. Among b/tsDMARD-treated patients, decreasing use of TNF-inhibitors (77.6–57.1%) and increasing IL-inhibitors (19.6–33.2%) was found across 2017–2020, respectively. Persistence to TNF-inhibitors and IL inhibitors as first-line ranged, respectively, 74.9–83.0% and 73.0–84.6%; specifically, 73.1–76.9% and 73.0–83.8% among bio-naïve, 83.3–90.0%, and 87.0% among bio-experienced. Among IXE-patients ( N = 178), 55.6% were bio-naïve, while 21.9% previously used secukinumab, 12.9% adalimumab, 10.1% etanercept. During a 1-year follow-up, 6.8% of IXE patients switched therapy. Conclusions This real-world study of PsA pharmacoutilization in Italy showed that more than one-third of patients were systemically untreated, and almost 20% were receiving biological medications. Among biological users, increasing use of IL-inhibitors and a decrease in TNF-inhibitors prescriptions over the years were found. A rather-high extent of persistency in treatment was observed. A focused analysis on IXE patients revealed over half of them to be bio-naïve, while around one-fourth were bio-experienced to IL inhibitors. Supplementary Information The online version contains supplementary material available at 10.1007/s40744-022-00440-1.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population

Perrone¹,

Losi

Filippi

et al. 2022

Rheumatol Ther

View full text Add to dashboard Cite

show abstract

“…Studies have reported biologic use for psoriasis increased from 2001-2005 to 2011-2015 period. 4 Our study aims to study longitudinal trends of 30-day readmissions of psoriasis patients in the US from 2010 to 2018, to see if increased biologic usage in more recent times has any effect on rates and outcomes of psoriasis readmissions.…”

Section: National Trends In Psoriasis Readmissions: a Longitudinal Study Of The Nationwide Readmission Database From 2010 To 2018mentioning

confidence: 99%

National trends in psoriasis readmissions: a longitudinal study of the nationwide readmission database from 2010 to 2018

Edigin

Pavon

Eseaton

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Biologics and small molecule inhibitors have diversified the psoriasis therapeutic landscape with little known about their impact on phototherapy usage 1‐4 . In this study, we examined phototherapy utilization for psoriasis in comparison with cutaneous T‐cell lymphoma (CTCL) and pruritus, and identified psoriasis treatment trends.…”

Section: Figurementioning

confidence: 99%

Trends in psoriasis treatment 2005 to 2018: Declining phototherapy utilization and concomitant increased use of biologics

Mytrang

Schwartz

Abedian

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Real-world trends in biologic, oral systemic, and phototherapy in US patients with psoriasis or psoriatic arthritis

Cited by 11 publications

References 1 publication

Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population

Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population

National trends in psoriasis readmissions: a longitudinal study of the nationwide readmission database from 2010 to 2018

Trends in psoriasis treatment 2005 to 2018: Declining phototherapy utilization and concomitant increased use of biologics

Contact Info

Product

Resources

About